Evidence map›Paper›PMID 25421459›Full record

ArticleThe AAPS journal2015

Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Jeremy A Bartlett, Marcus Brewster, Paul Brown, Donna Cabral-Lilly, Celia N Cruz, Raymond David, W Mark Eickhoff, Sabine Haubenreisser, Abigail Jacobs, Frank Malinoski and 12 more

Abstract read
In one paragraph

Article in The AAPS journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. The consolidation of nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jeremy A BartlettPfizer, Groton Laboratories, Groton, Connecticut, 06340, USA.
Marcus Brewster
Paul Brown
Donna Cabral-Lilly
Celia N Cruz
Raymond David
W Mark Eickhoff
Sabine Haubenreisser
Abigail Jacobs
Frank Malinoski
Elaine Morefield
Ritu Nalubola
Robert K Prud'homme
Nakissa Sadrieh
Christie M Sayes
Hripsime Shahbazian
Nanda Subbarao
Lawrence Tamarkin
Katherine Tyner
Rajendra Uppoor
Margaret Whittaker-Caulk
William Zamboni

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the Product Quality Research Institute (PQRI) Workshop held last January 14-15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of characterization, formulation development, manufacturing, and nonclinical safety evaluation of nanomaterial-containing drug products for human use. The workshop discussions identified areas where additional understanding of material attributes, absorption, biodistribution, cellular and tissue uptake, and disposition of nanosized particles would continue to inform their safe use in drug products. Analytical techniques and methods used for in vitro characterization and stability testing of formulations containing nanomaterials were discussed, along with their advantages and limitations. Areas where additional regulatory guidance and material characterization standards would help in the development and approval of nanomedicines were explored. Representatives from the US Food and Drug Administration (USFDA), Health Canada, and European Medicines Agency (EMA) presented information about the diversity of nanomaterials in approved and newly developed drug products. USFDA, Health Canada, and EMA regulators discussed the applicability of current regulatory policies in presentations and open discussion. Information contained in several of the recent EMA reflection papers was discussed in detail, along with their scope and intent to enhance scientific understanding about disposition, efficacy, and safety of nanomaterials introduced in vivo and regulatory requirements for testing and market authorization. Opportunities for interaction with regulatory agencies during the lifecycle of nanomedicines were also addressed at the meeting. This is a summary of the workshop presentations and discussions, including considerations for future regulatory guidance on drug products containing nanomaterials.

Indexed as

Drug DesignNanostructuresAnimalsChemistry, PharmaceuticalDrug and Narcotic ControlDrug ApprovalHumansNanoparticlesPharmaceutical PreparationsTissue DistributionPharmaceutical Preparations

Identifiers

PMID25421459
PMCPMC4287304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.